Immunoclin Corp

CIK:0001520047|SEC Filings

Nature Of Operations And Continuance Of Business (Narrative) (Details) (USD $)	Oct. 31, 2014
Nature Of Operations And Continuance Of Business Narrative Details
Working capital deficit	$ 2,595,392imcl_WorkingCapitalDeficit

Consolidated Statements Of Cash Flows (USD $)	9 Months Ended
Consolidated Statements Of Cash Flows (USD $)	Oct. 31, 2014	Oct. 31, 2013
Operating Activities
Net loss for the period	$ (7,909,746)us-gaap_NetIncomeLoss	$ (440,362)us-gaap_NetIncomeLoss
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization	1,153,845us-gaap_AmortizationOfIntangibleAssets
Depreciation	2,450us-gaap_Depreciation	1,448us-gaap_Depreciation
Amortization of prepaid consulting	499,528imcl_AmortizationOfPrepaidConsulting	194,960imcl_AmortizationOfPrepaidConsulting
Loss on settlement of liabilities	(5,198,700)
Unrealized gain on marketable securities	236,000
Foreign exchange translation	(42,662)	(26,228)
Changes in operating assets and liabilities:
Accounts receivable	52,557	11,448
Other receivables	6,079	4,373
Deposits	(3,000)us-gaap_IncreaseDecreaseInDeposits
Prepaid expenses	18,587
Accounts payable	244,688	37,320
Accrued expenses, primarily management fees	845,667	166,268
Deferred revenue	143,128
Net Cash Used In Operating Activities	(180,625)	(82,415)
Investing Activities
Purchase of property and equipment	6,348	1,318
Net Cash Used in Investing Activities	(6,348)	(1,318)
Financing Activities
Proceeds from related party loans	5,729us-gaap_ProceedsFromRelatedPartyDebt
Proceeds from notes payable, related party	275,000us-gaap_ProceedsFromNotesPayable
Net Cash Provided by Financing Activities	280,729
Change in Cash	93,756us-gaap_CashPeriodIncreaseDecrease	(83,733)us-gaap_CashPeriodIncreaseDecrease
Cash - Beginning of Period	51,956us-gaap_Cash	167,416us-gaap_Cash
Cash - End of Period	145,712us-gaap_Cash	83,683us-gaap_Cash
Supplemental Disclosures
Notes payable from legal trust deposit by third party	22,500	2,062
Notes payable from prepaid expenses paid by related party	15,000us-gaap_NotesAssumed1
Notes payable from accounts payable paid by related party	68,748us-gaap_LiabilitiesAssumed1
Notes payable from accounts payable paid by stockholder		16,312
Cancellation of common stock	93
Common stock issued for prepaid services	4,527,500	700,000
Common stock received for services	602,000
Unrealized gain on marketable securities	236,000us-gaap_MarketableSecuritiesGainLoss
Interest paid
Income tax paid

Consolidated Balance Sheets (USD $)	Oct. 31, 2014	Jan. 31, 2014
ASSETS
Cash	$ 145,712us-gaap_Cash	$ 51,956us-gaap_Cash
Accounts receivable	66,866us-gaap_AccountsReceivableNetCurrent	14,309us-gaap_AccountsReceivableNetCurrent
Other receivable	13,824us-gaap_OtherReceivablesNetCurrent	7,745us-gaap_OtherReceivablesNetCurrent
Prepaid expenses	18,587us-gaap_PrepaidExpenseCurrent
Current Assets	244,989us-gaap_AssetsCurrent	74,010us-gaap_AssetsCurrent
Deposits	3,000us-gaap_DepositAssets
Property and equipment, net (Note 7)	10,139us-gaap_PropertyPlantAndEquipmentNet	6,241us-gaap_PropertyPlantAndEquipmentNet
Intangibles, net (Note 8)	18,639,621us-gaap_FiniteLivedIntangibleAssetsNet	19,793,466us-gaap_FiniteLivedIntangibleAssetsNet
Goodwill	654,992us-gaap_Goodwill	654,992us-gaap_Goodwill
Marketable securities	838,000us-gaap_MarketableSecuritiesNoncurrent
Total Assets	20,390,741us-gaap_Assets	20,528,709us-gaap_Assets
Current Liabilities
Accounts payable	331,458us-gaap_AccountsPayableCurrent	177,817us-gaap_AccountsPayableCurrent
Accrued expenses, primarily management fees	1,315,555	469,888
Deferred revenue	745,128us-gaap_DeferredRevenueCurrent
Due to related parties (Note 4)	8,433us-gaap_DueToRelatedPartiesCurrent	2,704us-gaap_DueToRelatedPartiesCurrent
Notes payable, related parties (Note 5)	368,110	2,062
Notes payable, stockholders (Note 5)	71,697us-gaap_NotesPayableCurrent	72,997us-gaap_NotesPayableCurrent
Total Current Liabilities	2,840,381us-gaap_LiabilitiesCurrent	725,468us-gaap_LiabilitiesCurrent
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at October 31, 2014 and January 31, 2014. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at October 31, 2014 and January 31, 2014.	1,000us-gaap_PreferredStockValue	1,000us-gaap_PreferredStockValue
Common Stock, $0.001 par value, 290,000,000 shares authorized, 28,831,154 issued and outstanding October 31, 2014 and 26,503,515 at January 31, 2014	28,831us-gaap_CommonStockValue	26,504us-gaap_CommonStockValue
Prepaid consulting	(4,538,301)imcl_PrepaidConsulting	(510,329)imcl_PrepaidConsulting
Additional paid-in capital	42,889,446us-gaap_AdditionalPaidInCapital	33,164,274us-gaap_AdditionalPaidInCapital
Accumulated deficit	(20,772,515)	(12,862,769)
Cumulative translation adjustments	(58,101)	(15,439)
Total Stockholders' Equity	17,550,360us-gaap_StockholdersEquity	19,803,241us-gaap_StockholdersEquity
Total Liabilities and Stockholders' Equity	20,390,741	20,528,709
Series A Preferred Stock
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 9,000,000 shares authorized, 0 shares issued and outstanding at October 31, 2014 and January 31, 2014. Series A Preferred stock, $0.001 par value, 1,000,000 shares authorized, 1,000,000 shares issued and outstanding at October 31, 2014 and January 31, 2014.	1,000	1,000
Total Stockholders' Equity	1,000	1,000
Total Liabilities and Stockholders' Equity	$ 1,000	$ 1,000